Who is sponsoring NCT02330380?

NCT02330380 is sponsored by University Hospitals Cleveland Medical Center.

What condition does NCT02330380 study?

NCT02330380 studies Psoriasis, Inflammation.

What drugs are being tested in NCT02330380?

Interventions: Methotrexate, Ustekinumab, Etanercept, Adalimumab, Acitretin, UVB Excimer Laser, Narrowband UVB.

What is the status of NCT02330380?

NCT02330380 is currently COMPLETED.

Last reviewed 2017-10-12 · How we verify

Comparative Effectiveness of Psoriasis Treatments on Systemic Inflammation

NCT02330380 COMPLETED

This is a prospective longitudinal observational pilot study of psoriasis patients on continuous standard-of-care systemic therapeutics to determine the level of change in established (plasma/serum) and investigative (cellular) biomarkers that are associated with increased risk of CVD events. The final endpoint of the proposed study will be a ranking of the examined biomarkers based upon an integrated assessment of biomarker behavior over time. Secondary outcomes will assess changes in coronary artery calcification scoring, PET-MRI, skin biopsies, and clinical improvement.

Details

Lead sponsor	University Hospitals Cleveland Medical Center
Status	COMPLETED
Enrolment	26
Start date	2013-04
Completion	2016-12

Conditions

Psoriasis
Inflammation

Interventions

Methotrexate
Ustekinumab
Etanercept
Adalimumab
Acitretin
UVB Excimer Laser
Narrowband UVB

Primary outcomes

Biomarker assessment — 52 weeks
The biomarkers examined throughout the study will be assessed. And, an integrated assessment of biomarker behavior over time will be performed. Biomarkers examined will include High sensitivity C-reactive protein (hsCRP), Myeloperoxidase (MPO), resistin, adiponectin and leptin.

Countries

United States